Latanoprost Viatris (Latanoprost)

Latanoprost binds to FP receptors in the eye’s ciliary body, increasing uveoscleral outflow of aqueous humor. This enhanced drainage reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management.

The dosing regimen for Latanoprost Viatris is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, latanoprost often provides greater pressure reduction with a favorable dosing convenience, though individual response may vary.

Latanoprost Viatris should be stored at controlled room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from light, and avoid exposure to moisture to maintain product stability.

The medication is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, usually in the evening. Patients should wash their hands before use, avoid touching the tip of the bottle to the eye or any surface, and close the eyelid gently after instillation.

Serious but rare risks include a paradoxical increase in intra‑ocular pressure, uveitis, corneal edema, and severe allergic reactions such as swelling or rash around the eye. Any sudden visual changes, pain, or signs of infection should prompt immediate medical evaluation.

Patients with known hypersensitivity to latanoprost or any excipients in the formulation should avoid its use. Additionally, individuals using other prostaglandin analog eye drops simultaneously, or those with active ocular infections, should discuss alternatives with their ophthalmologist.